vs
Side-by-side financial comparison of Autolus Therapeutics plc (AUTL) and SOLESENCE, INC. (SLSN). Click either name above to swap in a different company.
Autolus Therapeutics plc is the larger business by last-quarter revenue ($21.2M vs $12.5M, roughly 1.7× SOLESENCE, INC.). SOLESENCE, INC. runs the higher net margin — 1.3% vs -373.3%, a 374.6% gap on every dollar of revenue.
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company specializing in the development of next-generation engineered chimeric antigen receptor T-cell (CAR-T) therapies for the treatment of hematological malignancies and solid tumors. It operates in the global oncology biotech market, advancing a pipeline of targeted immunotherapy candidates across multiple clinical development stages.
AUTL vs SLSN — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $21.2M | $12.5M |
| Net Profit | $-79.1M | $163.0K |
| Gross Margin | — | 27.5% |
| Operating Margin | -337.9% | 1.5% |
| Net Margin | -373.3% | 1.3% |
| Revenue YoY | — | -0.7% |
| Net Profit YoY | 3.6% | 129.2% |
| EPS (diluted) | $-0.30 | $0.00 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $12.5M | ||
| Q3 25 | $21.2M | $14.6M | ||
| Q2 25 | $20.9M | $20.4M | ||
| Q1 25 | $9.0M | $14.6M | ||
| Q4 24 | — | $12.6M | ||
| Q3 24 | $0 | $16.9M | ||
| Q2 24 | $0 | $13.0M | ||
| Q1 24 | $10.1M | $9.9M |
| Q4 25 | — | $163.0K | ||
| Q3 25 | $-79.1M | $-1.1M | ||
| Q2 25 | $-47.9M | $2.7M | ||
| Q1 25 | $-70.2M | $80.0K | ||
| Q4 24 | — | $-559.0K | ||
| Q3 24 | $-82.1M | $3.0M | ||
| Q2 24 | $-58.3M | $856.0K | ||
| Q1 24 | $-52.7M | $893.0K |
| Q4 25 | — | 27.5% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 28.9% | ||
| Q1 25 | — | 23.1% | ||
| Q4 24 | — | 22.0% | ||
| Q3 24 | — | 36.2% | ||
| Q2 24 | — | 28.7% | ||
| Q1 24 | — | 36.3% |
| Q4 25 | — | 1.5% | ||
| Q3 25 | -337.9% | -5.4% | ||
| Q2 25 | -292.6% | 9.4% | ||
| Q1 25 | -726.3% | 1.8% | ||
| Q4 24 | — | -1.8% | ||
| Q3 24 | — | 19.0% | ||
| Q2 24 | — | 8.0% | ||
| Q1 24 | -384.1% | 11.3% |
| Q4 25 | — | 1.3% | ||
| Q3 25 | -373.3% | -7.7% | ||
| Q2 25 | -229.0% | 13.1% | ||
| Q1 25 | -781.1% | 0.5% | ||
| Q4 24 | — | -4.4% | ||
| Q3 24 | — | 18.1% | ||
| Q2 24 | — | 6.6% | ||
| Q1 24 | -522.1% | 9.0% |
| Q4 25 | — | $0.00 | ||
| Q3 25 | $-0.30 | $-0.02 | ||
| Q2 25 | $-0.18 | $0.04 | ||
| Q1 25 | $-0.26 | $0.00 | ||
| Q4 24 | — | $0.00 | ||
| Q3 24 | $-0.31 | $0.04 | ||
| Q2 24 | $-0.22 | $0.01 | ||
| Q1 24 | $-0.24 | $0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $86.1M | $1.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $265.5M | $17.6M |
| Total Assets | $661.9M | $50.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.3M | ||
| Q3 25 | $86.1M | $429.0K | ||
| Q2 25 | $123.8M | $4.1M | ||
| Q1 25 | $95.8M | $1.8M | ||
| Q4 24 | — | $1.4M | ||
| Q3 24 | $657.1M | $2.9M | ||
| Q2 24 | $705.9M | $2.4M | ||
| Q1 24 | $758.5M | $2.0M |
| Q4 25 | — | $17.6M | ||
| Q3 25 | $265.5M | $17.2M | ||
| Q2 25 | $346.5M | $18.2M | ||
| Q1 25 | $371.1M | $15.2M | ||
| Q4 24 | — | $14.9M | ||
| Q3 24 | $477.0M | $15.2M | ||
| Q2 24 | $527.8M | $11.9M | ||
| Q1 24 | $582.0M | $5.0M |
| Q4 25 | — | $50.1M | ||
| Q3 25 | $661.9M | $54.0M | ||
| Q2 25 | $721.0M | $60.0M | ||
| Q1 25 | $746.3M | $57.0M | ||
| Q4 24 | — | $50.0M | ||
| Q3 24 | $827.5M | $48.0M | ||
| Q2 24 | $853.6M | $40.8M | ||
| Q1 24 | $901.4M | $38.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-67.9M | $1.8M |
| Free Cash FlowOCF − Capex | $-72.3M | — |
| FCF MarginFCF / Revenue | -341.2% | — |
| Capex IntensityCapex / Revenue | 20.8% | — |
| Cash ConversionOCF / Net Profit | — | 11.16× |
| TTM Free Cash FlowTrailing 4 quarters | $-322.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $1.8M | ||
| Q3 25 | $-67.9M | $-2.5M | ||
| Q2 25 | $-72.8M | $-654.0K | ||
| Q1 25 | $-75.6M | $-7.2M | ||
| Q4 24 | — | $2.2M | ||
| Q3 24 | $-76.7M | $4.2M | ||
| Q2 24 | $-51.1M | $-565.0K | ||
| Q1 24 | $-40.5M | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | $-72.3M | — | ||
| Q2 25 | $-80.1M | — | ||
| Q1 25 | $-83.8M | — | ||
| Q4 24 | — | $-404.0K | ||
| Q3 24 | $-86.3M | $2.8M | ||
| Q2 24 | $-51.9M | $-1.0M | ||
| Q1 24 | $-41.0M | $-3.9M |
| Q4 25 | — | — | ||
| Q3 25 | -341.2% | — | ||
| Q2 25 | -382.6% | — | ||
| Q1 25 | -933.1% | — | ||
| Q4 24 | — | -3.2% | ||
| Q3 24 | — | 16.6% | ||
| Q2 24 | — | -8.0% | ||
| Q1 24 | -406.8% | -39.9% |
| Q4 25 | — | — | ||
| Q3 25 | 20.8% | — | ||
| Q2 25 | 34.8% | — | ||
| Q1 25 | 91.8% | — | ||
| Q4 24 | — | 20.6% | ||
| Q3 24 | — | 8.3% | ||
| Q2 24 | — | 3.7% | ||
| Q1 24 | 5.3% | 0.9% |
| Q4 25 | — | 11.16× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.25× | ||
| Q1 25 | — | -90.26× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.38× | ||
| Q2 24 | — | -0.66× | ||
| Q1 24 | — | -4.32× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
